CTOs on the Move

Oncocyte

www.oncocyte.com

 
Oncocyte’s mission is to provide tests to physicians and patients that provide answers at critical decision points during lung cancer diagnosis.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.oncocyte.com
  • 1010, Atlantic Avenue
    Alameda, CA USA 94501
  • Phone: 949.409.7600

Executives

Name Title Contact Details

Similar Companies

MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology to develop products that improve patient outcomes and address unmet needs. These pharmaceutical and over-the-counter products are developed independently and with partners. PharmFilm can provide a benefit to patients by improving the efficacy, safety, and convenience of currently marketed pharmaceutical products. PharmFilm enhances new pharmaceutical products with the unique, multi-faceted value proposition afforded by film delivery. MonoSol Rx`s leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film.

Cambria Biosciences

Cambria Biosciences is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hexagon Bio

Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics.

Seven Bridges

Personalized medicine, drug discovery, diagnostic testing, and foundational genomic research all start with bioinformatics. The world`s largest research institutions use Seven Bridges` software platform to help them analyze, store, and act on genomic and other biological data.

Sensei Biotherapeutics

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.